Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

NCT01843374 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01843374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01843374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 17, 2013
Completion date
May 31, 2027
Enrollment
571 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable pleural or peritoneal malignant mesothelioma